FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 277 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... September 22, 2021 “Giving something back”: our supporters are the beating heart of what... August 17, 2022 Olivia Newton-John Shares Positive News On Breast Cancer: “I’m Winning Over... January 28, 2020 Opinion: “There’s cause for optimism in 2021 and beyond” December 30, 2020 Load more HOT NEWS Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients... Men’s skin cancer rates increase by 50% over decade EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients For Children with Retinoblastoma, Disparities Seen across the Globe
